Evidence map›Paper›PMID 26273092›Full record

ArticleCirculation. Cardiovascular genetics2015

Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures.

Audrey Y Chu, Franco Giulianini, Bryan J Barratt, Bo Ding, Fredrik Nyberg, Samia Mora, Paul M Ridker, Daniel I Chasman

Registry-linked trialOpen access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Cardiovascular genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00239681 (A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00239681 phase3terminatednot on this map

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein

TypeinterventionalSponsorAstraZenecaRan2003 to 2008Enrolled17,802ConditionsElevated High-sensitivity C-Reactive Protein (hsCRP)ArmsRosuvastatin, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Audrey Y ChuFrom the Division of Preventive Medicine (A.Y.C., F.G., S.M., P.M.R., D.I.C.), Division of Cardiovascular Medicine (S.M., P.M.R.), Division of Genetics (D.I.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Personalised Healthcare and Biomarkers AstraZeneca Research and Development, Alderley Park, United Kingdom (B.J.B.); Observational Research Center, AstraZeneca Research and Development, Mölndal (B.D., F.N.); and Unit of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (F.N.). aychu@partners.org.
Franco GiulianiniFrom the Division of Preventive Medicine (A.Y.C., F.G., S.M., P.M.R., D.I.C.), Division of Cardiovascular Medicine (S.M., P.M.R.), Division of Genetics (D.I.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Personalised Healthcare and Biomarkers AstraZeneca Research and Development, Alderley Park, United Kingdom (B.J.B.); Observational Research Center, AstraZeneca Research and Development, Mölndal (B.D., F.N.); and Unit of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (F.N.).
Bryan J BarrattFrom the Division of Preventive Medicine (A.Y.C., F.G., S.M., P.M.R., D.I.C.), Division of Cardiovascular Medicine (S.M., P.M.R.), Division of Genetics (D.I.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Personalised Healthcare and Biomarkers AstraZeneca Research and Development, Alderley Park, United Kingdom (B.J.B.); Observational Research Center, AstraZeneca Research and Development, Mölndal (B.D., F.N.); and Unit of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (F.N.).
Bo DingFrom the Division of Preventive Medicine (A.Y.C., F.G., S.M., P.M.R., D.I.C.), Division of Cardiovascular Medicine (S.M., P.M.R.), Division of Genetics (D.I.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Personalised Healthcare and Biomarkers AstraZeneca Research and Development, Alderley Park, United Kingdom (B.J.B.); Observational Research Center, AstraZeneca Research and Development, Mölndal (B.D., F.N.); and Unit of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (F.N.).
Fredrik NybergFrom the Division of Preventive Medicine (A.Y.C., F.G., S.M., P.M.R., D.I.C.), Division of Cardiovascular Medicine (S.M., P.M.R.), Division of Genetics (D.I.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Personalised Healthcare and Biomarkers AstraZeneca Research and Development, Alderley Park, United Kingdom (B.J.B.); Observational Research Center, AstraZeneca Research and Development, Mölndal (B.D., F.N.); and Unit of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (F.N.).
Samia MoraFrom the Division of Preventive Medicine (A.Y.C., F.G., S.M., P.M.R., D.I.C.), Division of Cardiovascular Medicine (S.M., P.M.R.), Division of Genetics (D.I.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Personalised Healthcare and Biomarkers AstraZeneca Research and Development, Alderley Park, United Kingdom (B.J.B.); Observational Research Center, AstraZeneca Research and Development, Mölndal (B.D., F.N.); and Unit of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (F.N.).
Paul M RidkerFrom the Division of Preventive Medicine (A.Y.C., F.G., S.M., P.M.R., D.I.C.), Division of Cardiovascular Medicine (S.M., P.M.R.), Division of Genetics (D.I.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Personalised Healthcare and Biomarkers AstraZeneca Research and Development, Alderley Park, United Kingdom (B.J.B.); Observational Research Center, AstraZeneca Research and Development, Mölndal (B.D., F.N.); and Unit of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (F.N.).
Daniel I ChasmanFrom the Division of Preventive Medicine (A.Y.C., F.G., S.M., P.M.R., D.I.C.), Division of Cardiovascular Medicine (S.M., P.M.R.), Division of Genetics (D.I.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Personalised Healthcare and Biomarkers AstraZeneca Research and Development, Alderley Park, United Kingdom (B.J.B.); Observational Research Center, AstraZeneca Research and Development, Mölndal (B.D., F.N.); and Unit of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (F.N.).
University of Gothenburg · SEAstraZeneca (United Kingdom) · GB

Funding

Training Program in the Epidemiology of CVDT32HL007575 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BURING, JULIE E., RIDKER, PAUL M. · 1985 to 2019
$5.0M
Total plasma and IgG glycomes, statin therapy and ASCVD eventsR01HL117861 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2013 to 2022
$3.8M
NHLBI NIH HHS R01 HL117861NHLBI NIH HHS R01HL117861NHLBI NIH HHS T32 HL007575NHLBI NIH HHS T32HL757520
6 · The paper itself

Abstract

backgroundStatin therapy influences not only low-density lipoprotein (LDL) cholesterol levels but also LDL-related biomarkers, including non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B, total number of LDL particles, and mean LDL particle size. Recent studies have identified many genetic loci influencing circulating lipid levels and statin-induced LDL cholesterol reduction. However, it is unknown how these genetic variants influence statin-induced changes in LDL subfractions and non-HDL-C. METHODS AND

resultsOne hundred sixty candidate single-nucleotide polymorphisms for effects on circulating lipid levels or statin-induced LDL-cholesterol lowering were tested for association with response of LDL subfractions and non-HDL-C to rosuvastatin or placebo for 1 year among 7046 participants from the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Of the 51 single-nucleotide polymorphisms associated with statin response for ≥ 1 of the LDL subfractions or non-HDL-C, 20 single-nucleotide polymorphisms could be clustered according to effects predominantly on LDL particle size, predominantly on LDL particle number, and on apolipoprotein B but not on LDL cholesterol or non-HDL-C.

conclusionsThese differential associations point to pathways of LDL response to statin therapy and possibly to mechanisms of statin-dependent cardiovascular disease risk reduction. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681.

Indexed as

Polymorphism, Single NucleotideFemaleGenetic MarkersHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins, LDLMaleRosuvastatin CalciumGenetic MarkersHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins, LDLRosuvastatin Calciumcholesterolgeneticsgenome-wide association studylipoproteins, LDLNMR spectroscopyrosuvastatin

Identifiers

PMID26273092
PMCPMC4618030
OpenAlexW2102248325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.